The importance of maternal cholesterol as an exogenous cholesterol source for the growing embryo was first reported in studies of Smith-Lemli-Opitz syndrome. Although most of the fetus's cholesterol is synthesized by the fetus itself, there is now growing evidence that during the first weeks of life, when most organs develop, the fetus largely depends on maternal cholesterol as its cholesterol source. The maternal-fetal cholesterol transport mechanism, by transporters in both the yolk sac and placenta, is becoming better understood. This minireview summarizes current insights on maternal-fetal cholesterol transport based on in vitro and in vivo studies. As the prevalence of maternal diseases, such as diabetes, obesity, and the metabolic syndrome that adversely affect maternal cholesterol levels, is now rapidly reaching epidemic proportions, we urgently need to determine the impact of these maternal conditions on the developing human fetus. cholesterol, embryology, placenta, placental transport, yolk sac
INTRODUCTION
Cholesterol is present in every cell of the human body. It helps maintaining the integrity of cell membranes and plays an important role in cell signaling. Cholesterol is a precursor for all steroid hormones and bile acids and also plays a crucial role in early fetal development: it moderates the sonic hedgehog (SHH) proteins and important nuclear receptors such as fetoprotein transcription factor and is therefore involved in the most fundamental signaling pathways during embryonic development. SHH proteins play a role in migration and survival of neural crest cells, a population of cells that highly contribute to the development of the brain, limbs, lungs, heart and urogenital system [1, 2] . Fetoprotein transcription factor, also known as NR5A2, can bind GATA elements, essential for the development of many organ systems, and is also highly expressed in the neural crest cells [3, 4] .
It is assumed that most of the fetus's cholesterol is synthesized by the fetus itself, mainly by the fetal liver [5] although evidence is growing that during the first weeks of life, when most organs are formed, the fetus depends largely on maternal cholesterol. Recent data show that the by-products of endogenous fetal cholesterol synthesis in amniotic fluid, dihydrolanosterol, lanosterol, and lathosterol are very low until the 19th week of pregnancy, after which their levels increase strongly [6] . Together with relatively constant levels of total cholesterol in the amniotic fluid and the presence of maternally derived cholesterol (measured as b-sitosterol) during the same period, these data suggest that maternal cholesterol plays a crucial role in providing the cholesterol for fetal development.
If the fetus is indeed dependent on a maternal supply of cholesterol during early pregnancy, then diseases affecting maternal cholesterol levels may have an adverse effect on the development and growth of the fetus. The aim of this review is to summarize current insights on maternal-fetal cholesterol transport based on in vitro and in vivo studies, and to emphasize the importance of maternal cholesterol in early human pregnancy. As the prevalence of diseases that influence maternal cholesterol levels, like obesity and dyslipidemia (as part of the metabolic syndrome) is reaching epidemic proportions, the impact of these maternal conditions on the growing fetus needs to be determined.
CHOLESTEROL AND DEVELOPMENT
The role of cholesterol in early human development begins before implantation. Cholesterol serves as the precursor for progesterone synthesis and it is essential for early fetal development as it helps maintain the early pregnancy [7] .
High density lipoprotein (HDL) cholesterol levels are directly correlated to reproductive outcome (reviewed in [8] . During early embryonic development, both HDL and low density lipoprotein (LDL) cholesterol particles seem to play an important role. LDL cholesterol is the main precursor for progesterone synthesis by the corpus luteum, but HDL particles also deliver cholesterol for progesterone synthesis [9] .
Once the embryo is implanted in the uterine wall, cholesterol is crucial for further embryogenesis. It activates the SHH proteins and propagates their signals which, through the family of GLI transcription factors, activate and repress target genes responsible for the development of different organ systems such as the neural tube, brain, limbs and heart [10] [11] [12] . Distal inhibition of the cholesterol biosynthesis pathway by using a pharmacologic agent, which inhibits SHH transcription, causes severe birth defects in vivo. These defects include holoprosencephaly, neural tube defects, and heart and limb anomalies [13] . Furthermore, mutations in genes coding for enzymes required for human cholesterol biosynthesis are associated with the same kind of birth defects, which can be demonstrated by the birth defects present in Smith-Lemli-Opitz syndrome (SLOS) [14] . The underlying cause of SLOS is a mutation in both alleles of the DHCR7 gene, leading to an impairment in the conversion of 7-dehydrocholesterol into cholesterol, resulting in an accumulation of 7-dehydrocholesterol and a shortage or complete absence of cholesterol in the fetus [15] . Children with SLOS are born with severe congenital anomalies including holoprosencephaly, heart anomalies, and postaxial polydactyly and are often mentally retarded. A shortage of cholesterol early in life probably disrupts the SHH-GLI signal transduction pathway [16] . Interestingly, in children with a null-mutation of the DHCR7 gene, and thus lacking endogenous cholesterol synthesis, some cholesterol is still detectable in cells and plasma after birth [17] . These data suggest that there must be an exogenous source providing some of the cholesterol needed for fetal development and growth in these fetuses.
TRANSPORT OF MATERNAL CHOLESTEROL TO THE FETUS
Because it was reported that maternal cholesterol crosses the placental membranes and enters the fetal circulation [18] , further studies have focused on the role of maternal cholesterol in fetal development both in animals and in humans. We and others have shown that maternal cholesterol contributes substantially to the fetal cholesterol pool in both animals and humans [6, 19, 20] . Vuorio et al. [21] reported that just after birth, plant sterol concentrations in cord blood of healthy newborns were 40%-50% of the maternal levels, indicative for active maternal-fetal sterol transport. From these studies, we can conclude that a significant amount of fetal cholesterol is derived from the mother. Before we describe maternal cholesterol levels and maternal-fetal cholesterol transport in relationship to pregnancy outcomes in both animals and humans, we first discuss current knowledge of the maternalfetal cholesterol transport mechanism.
Maternal-Fetal Cholesterol Transport Mechanisms
Secondary yolk sac. During the first 8 wk of human development, when most organs are formed and before uteroplacental circulation is established, the secondary yolk sac plays an important role in maternal-fetal cholesterol exchange. The secondary yolk sac floats within the exocoelomic cavity between the placenta and the amniotic cavity and is directly connected to the embryonic gut and to the fetal circulation through the vitelline duct [22] . Molecules from the mother leak into the exocoelomic cavity, are taken up by the membrane of the secondary yolk sac, transported across their membranes, and excreted to the fetal circulation [23, 24] . Figure 1 summarizes the proposed maternal-fetal cholesterol transport mechanism through the secondary yolk sac in humans. Lipoprotein receptors which are expressed on the visceral endoderm of the human secondary yolk sac are: scavenger receptor class B type 1 (SR-B1), intrinsic factorcobalamin receptor (cubilin), and low-density lipoprotein receptor-related protein 2 (LRP2; megalin), and the lowdensity lipoprotein receptor (LDLR) in large amounts. Table 1 summarizes the function and localization of these different receptor proteins. Furthermore, genotype-phenotype correlations are shown for both animal KO (KO) models and human mutations.
The human secondary yolk sac excretes apolipoprotein A1 (APOA1), APOE, and APOB in the form of lipoprotein particles (HDL, LDL, and very low density lipoprotein [VLDL]) [25] . The current authors believe that these lipoprotein complexes deliver maternal cholesterol to the fetus before vascularization of the chorionic villi is established. This has already been proven for maternally derived antioxidants that are detectable in the fetal gut and fetal circulation during early human pregnancy. These authors state that the secondary yolk sac plays a major role in this maternal-fetal transfer mechanism. In mice, microsomal triglyceride transfer protein (MTTP) is also detectable in the yolk sac. These MTTPs seem to play an important role in transferring cholesteryl esters between membranes and in the efflux of cholesterol bound to APOB particles into the fetal circulation [26] .
Placenta. At approximately 8 wk of human fetal development, the secondary yolk sac regresses and the placenta (trophoblast) takes over its nutritional role. At that stage, two cell layers separate the fetal circulation from the maternal circulation: the trophoblast (later the syncytiotrophoblast), and the endothelium. The human trophoblast expresses many lipoprotein receptors (Table 1) : the LDLR, very-low-densitylipoprotein receptor (VLDLR), class A scavenger receptors (SCARA), LRP2, cubilin, APOE receptor 2 (LRP8), LDL receptor-related protein (LRP1), and SR-B1 (reviewed in ref. [27] ).
Many studies in both animals and humans have reported cholesterol transfer through the trophoblast layer, carried in HDL and LDL particles, and this mechanism seems to be relatively well understood [28] [29] [30] . Once cholesterol is taken up on the apical (maternal) side of the trophoblast by receptordependent and receptor-independent processes, it is transported to the lysosome where these cholesterylesters bound to lipoproteins are hydrolyzed into free cholesterol. After being hydrolyzed, the cholesterol is bound to sterol carrier proteins and transferred to the basolateral membrane of the trophoblast/ syncytiotrophoblast. Basolateral excretion is still poorly defined, but may involve ABCG1 and possibly ABCA1. Finally, efflux to fetal lipoproteins containing APOA1, APOE, and APOB is mediated by the ABCA1 and ABCG1 transporters [31] [32] [33] [34] . This process, similar to the situation in the yolk sac, is facilitated by MTTP. Recently, Scholler et al. [35] reported a novel step in the maternal-fetal cholesterol transport mechanism by phospholipid transfer protein (PLTP). PLPT is expressed in the placental endothelium where it acts as a mediator in the formation of HDL particles. Furthermore, it enhances cholesterol efflux by interaction with ABCA1 [36] . However, the mechanism of cholesterol transfer from the basolateral membrane of the trophoblast cells to that of the BAARDMAN ET AL. endothelium, where it is being excreted to the fetus, is still largely unknown.
The expression of several genes involved in cholesterol transport is regulated by the liver-X receptors (LXR). LXRa and LXRb are activated by the presence of oxysterols, oxidized cholesterol derivatives, which are formed both by (regulated) enzymatic and by nonenzymatic processes [37, 38] . Hence, LXRs are thought to be key players of cholesterol homeostasis. We have previously proposed that during development, LXR activation may have therapeutic value under some circumstances by increasing maternal-fetal transport [39] , which has now been demonstrated in an animal model [40] . Figure 2 displays the proposed route of maternally derived cholesterol through the membranes of the trophoblast, from binding to cholesterol acceptors on the apical membrane of the trophoblast to excretion via cholesterol transporters on the basolateral membrane of the endothelium into the fetal circulation.
MATERNAL CHOLESTEROL LEVELS IN PREGNANCY
Besides an adequate maternal-fetal cholesterol transport mechanism, maternal cholesterol levels may also be important to meet fetal cholesterol demands during organogenesis. In pregnancy, maternal total cholesterol levels increase by 30%-50% as a result of enhanced cholesterol synthesis in the liver. This increased cholesterol synthesis already starts during the first trimester but is the highest in the third trimester of pregnancy [41] [42] [43] . Interestingly, during the first trimester of pregnancy, only HDL cholesterol is significantly increased [41] . From these studies one can hypothesize that lowering of total cholesterol could have an adverse effect on pregnancy outcome.
Low Maternal Cholesterol and Adverse Pregnancy Outcomes
In the literature there are several reports of adverse pregnancy outcomes in relation to low maternal cholesterol levels. Edison et al. [44] found associations between low maternal serum cholesterol and adverse pregnancy outcomes, including microcephaly and growth retardation. Sattar et al. [45] and Pecks et al. [46] reported the same finding of lower concentration levels of LDL cholesterol and total cholesterol in maternal serum of pregnancies complicated by intrauterine growth restriction.
An increasing number of hypercholesterolemic women between 20 and 40 years of age are eligible for treatment with lipid-lowering therapy such as statin drugs [47] . The risk of [48] showed congenital anomalies in onethird of pregnancies exposed to statin drugs. Most defects could be related to a disruption of SHH signaling. However, the postsurveillance study by Manson and colleagues [49] did not show any associations between intrauterine exposure to statin drugs and congenital anomalies. A prospective cohort study of 64 exposed and 64 nonexposed women did not show any increase in the risk for congenital anomalies in the offspring of mothers taking statin drugs during the first trimester of pregnancy [50] . These numbers however are small and inconclusive. Whether intrauterine exposure to statin drugs increases the risk for congenital anomalies in offspring still needs to be elucidated.
MATERNAL-FETAL CHOLESTEROL
In 2004, Witsch-Baumgarter et al. [51] reported that the maternal APOE genotype could modify the outcome of pregnancy in SLOS, resulting in a milder phenotype in offspring possibly because of the more rapid maternal-fetal cholesterol transport. Recently, Lanthaler and colleagues [52] also discovered that specific maternal ABCA1 genotypes are associated with the severity of SLOS in offspring. From these studies we can conclude that disturbances in maternal cholesterol levels are associated with adverse pregnancy outcomes. To date, however, there is no direct association between maternal dyslipidemia and fetal congenital anomalies [53] .
Animal KO Models for Cholesterol Transporter Proteins and Human Equivalents
Although a direct association between maternal dyslipidemia and fetal congenital anomalies in humans has not been proven yet, in animals the evidence for such an association is accumulating. Here we summarize the KO models with adverse pregnancy outcomes of the cholesterol transporter proteins that function as receptors on maternal-fetal membranes and those that are involved with intracellular cholesterol transport or efflux. We also report the human equivalents with known mutations in these genes.
The first example is the SR-B1 (also known as SCARB1) KO mouse, previously mentioned as HDL cholesterol transporter on yolk sac and placenta (Table 1) , whose offspring are malformed and display severe developmental arrest very early in pregnancy. As Scarb1 À/À mice born to heterozygous mothers are normal, this model indicates that the maternal lipid profile is crucial for fetal development in mice [54] . Recently, the first functional mutation in the SCARB1 gene in humans was identified. This missense mutation, known as P297S, leads to a 50% reduction in the uptake of HDL cholesterol in murine hepatocytes. In contrast to the effect of SR-B1 loss of function in mice, the only clinical symptoms in humans are elevated HDL cholesterol levels, altered platelet function, and decreased adrenal steroidogenesis. To date, there are no reports of an increased number of offspring with congenital anomalies [55, 56] .
Mice that lack the endocytic receptor cubilin, involved in HDL cholesterol transport, have offspring with severe malformations (Table 1) [57] . Cubilin is dependent on LRP2 to mediate HDL cholesterol uptake by the yolk sac and placenta [58] . LRP2 is an endocytic receptor which internalizes multiple ligands including APOE [59] and APOB [60] and is highly expressed in the yolk sac and the placenta [61] . LRP2-deficient mice are born with severe congenital anomalies affecting the forebrain, heart, lungs and kidneys, and most pups die within 24 hours after birth [62] . It is still unknown whether HDL (high) /APOB (low) [55] Yolk sac: rodents [94, 95] Early fetal loss, developmental arrest [96] Decreased platelet aggregation, high plasma HDL-C [55] Placenta: humans [29] , rodents [95] Cubilin APOA1 (high)/HDL (high) [97] Yolk sac: rodents [98, 99] Early fetal loss, malformations, somites [57] Megaloblastic anemia, vitamin B12 deficiency [101] Placenta: humans [100] , rodents [58] Low-density lipoprotein receptorrelated protein 2 APOE-VLDL (high); APOJ (high) [102] Yolk sac: rodents [103] Multiple congenital anomalies [62] Donnai-Barrow syndrome; multiple congenital anomalies [66] Placenta: humans [100, 104] , rodents [105] Low-density lipoprotein receptor APOB-LDL (high) [106] ; APOE-VLDL(high) [107] Yolk sac, trace amounts: rodents [108] Pro-atherosclerotic phenotype [110] Homozygous familial hypercholesterolemia [111, 112] Placenta: humans [109] , rodents [108] Low-density lipoprotein receptorrelated protein 8 APOE-VLDL (high); APOE-LDL (low) [113] Placenta: rodents [113] Pro-atherosclerotic phenotype [114] Premature coronary artery disease [115] Scavenger receptor class A type 1/2
Oxidized LDL (high) [116] Placenta: humans [116] , mammals [117] Protection from diet-induced atherosclerotic lesions [118] Prostatic cancer [119] Very-low-density lipoprotein receptor APOE-VLDL (high) [120, 121] Placenta: humans [122, 123] , rodents [124] Retinal angiomatous proliferation [125] Cerebellar hypoplasia and mental retardation [126] Low-density lipoprotein receptorrelated protein 1 APOE-VLDL (high) [127] Placenta: humans [128] , rodents [129] Pro-atherosclerotic phenotype [130] Association with Alzheimer disease [131] BAARDMAN ET AL.
these congenital anomalies are related to a depletion of fetal cholesterol due to decreased maternal-fetal cholesterol transport, or by a disruption of signaling pathways, As both cubilin and LRP2 also bind signaling molecules such as bone morphogenetic proteins [63] and SHH proteins [64] . Recently, a homozygous frame shift mutation in the cubilin gene was detected in patients with proteinuria, but none of the patients had congenital anomalies [65] . Carriers of LRP2 mutations, including small deletions or insertions causing frame shifts, nonsense, and missense mutations, suffer from Donnai-Barrow syndrome, a rare, autosomal recessive disorder characterized by corpus callosum agenesis, dysmorphic facial features, sensorineural deafness, congenital hernia diaphragmatica, proteinuria, and often congenital heart anomalies [66, 67] . Interestingly, LRP2 is the first cholesterol transporter that, if its function is arrested, causes the same clinical features in both mice and humans. It is therefore likely that LRP2 plays a crucial role in development not only in mice, but also in humans.
In the ABCA1 KO mouse, severe malformations are frequently observed in Abca1 À/À and Abca1 þ/À placenta. Moreover, both prenatal and early neonatal survival of
Abca1
À/À offspring is much lower than the expected Mendelian ratio [68] . ABCA1 is involved in cholesterol efflux to HDL cholesterol. Mutations in the ABCA1 gene in humans that lead to a defective ABCA1 transporter can cause both Tangier disease, an inherited, autosomal recessive disorder, and a subtype of familial HDL deficiency, an inherited, autosomal dominant disorder [69] [70] [71] . Tangier disease is characterized by neuropathy, enlarged tonsils, corneal clouding, hepatosplenomegaly, and premature cardiovascular disease. There are no reports of a high incidence of congenital anomalies. Familial HDL deficiency is one of the causes of premature coronary artery disease. Both diseases are characterized by low HDL cholesterol levels, resulting in an increased risk for atherosclerosis. Neither Tangier disease nor HDL deficiency is known to be associated with placental malformation or developmental arrest in offspring, as described in the animal KO model. The number of cases identified worldwide, however, is small.
Homozygous APOB KO mice display severe developmental arrest with a high resorption rate in utero, and exencephalus. The few mice that survive after weaning develop hydrocephalus [72] [73] [74] . Neural tube defects occur together with hydrocephalus in heterozygous APOB KO mice [75] . APOB 
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is bound to LDL cholesterol particles and crucial for the clearance and transport of LDL cholesterol. Humans with nonsense or frameshift mutations in the APOB gene leading to a truncated APOB species suffer from hypobetalipoproteinemia, causing increased LDL levels and an increased risk for atherosclerosis. To date, there are no reports of an increased risk for birth defects in humans [76] .
Most mice that lack the gene that encodes MTTP die in midgestation. The few that die later in pregnancy display severe exencephalus [26] . MTTP is crucial for lipoprotein-related transport of cholesterol [26] . Mutations in the MTTP gene that lead to a reduction of MTTP activity have been described in humans and cause abetalipoproteinemia, an inherited recessive disease that is marked by little to no circulating levels of VLDL and LDL, resulting in malabsorption of fat-soluble vitamins and a failure to thrive. Birth defects in humans have not been described [77] .
Besides LRP2, in which both the animal KO model and a mutation in humans give rise to severe congenital anomalies in offspring, the absence of cholesterol transporter proteins involved in maternal-fetal cholesterol transport are to date only associated with adverse pregnancy outcomes in mice. One explanation for this might be that the pregnancy of mice differs from that of humans in many ways. The most important difference is the function of the secondary yolk sac, which in mice regresses during mid-gestation but in humans already regresses before the 12th wk of pregnancy [78] . Therefore, transporters that are mainly expressed on the yolk sac, such as SR-B1, can cause congenital anomalies in the offspring of mice [54] but not in humans [56] . However, the human genotype of SCARB1 mutation has only recently been described and the total number of patients is very small. It is possible that an association between a homozygous SCARB1 mutation and congenital anomalies will be found in the future.
CONCLUSIONS AND PERSPECTIVES
In this minireview, we have attempted to summarize the basic mechanisms of maternal-fetal cholesterol transport with emphasis on clinical consequences of their failure. Most of these data support the hypothesis that, during early fetal life, maternal cholesterol could be the most important source of cholesterol for the growing embryo. Shortage of maternal cholesterol may therefore result in congenital anomalies in the offspring. Obviously, the numbers of human cases of the genetic defects described are low and are not conclusive. In the near future next generation sequencing may help us to reveal more pathogenic mutations in humans and their genotypephenotype correlation.
The Western world faces a large and increasing number of individuals with aberrant lipid profiles related to our unhealthy life style. In Western countries, the prevalence of diseases that influence cholesterol levels, such as diabetes mellitus (DM) and obesity, are increasing dramatically among pregnant women. In the United Kingdom, for example, the prevalence of maternal obesity has doubled over the last 20 years [79] . Both obesity and DM result in changes in the mother's lipid profile, with plasma LDL cholesterol rising and HDL cholesterol falling [80] . Dyslipidemia in mothers with DM results in similar lipid profiles in the offspring [81] . Children of women who have either obesity or DM do indeed appear to have an increased risk of congenital anomalies [82] [83] [84] .
Oxidative stress is one mechanism proposed to play a role in the cause of congenital anomalies in the offspring of these women [85, 86] . The increase in oxidative stress in both obesity and DM [87] has many adverse side effects including increased levels of oxysterols in blood which are known to be toxic for cells [88] [89] [90] . In animals, it has already been shown that the increase of oxysterols in SLOS contributes to the disease [91] . Furthermore, nuclear receptors in the trophoblast recognize oxysterols as endogenous ligands [92, 93] . It is therefore possible that they also cross the placenta to assert their effect on the development of the fetus, although this has not yet been demonstrated.
Besides oxidative stress, we also believe that changes in plasma lipid composition during maternal obesity and diabetes also contribute to the increased risk for fetal malformations, because cholesterol, especially HDL cholesterol, might be of crucial importance during early fetal life. A reduction in maternal-fetal HDL cholesterol transport in humans in the first trimester of pregnancy could therefore act as a negative modifier of fetal development, especially in those children that already have a genetic susceptibility for congenital anomalies due to mutations in cholesterol related genes.
Because early intervention aimed at normalizing cholesterol levels could possibly prevent congenital anomalies in offspring of those who already have a genetic susceptibility, further study of the role played by maternal cholesterol in early fetal development is urgently required. As an example, in utero treatment with an LXR agonist, as we previously suggested [39] , has been successfully applied in an animal model of SLOS and resulted in milder phenotypes [40] .
In the long term, population studies of large numbers of women with dyslipidemia, including information about their blood cholesterol levels and genetic lipid profiles and thorough examination of the offspring, will be needed to elucidate whether maternal cholesterol is the key factor relating DM and obesity to an increased prevalence of congenital malformations in the offspring.
